- Home
- LODE vs MAIA Comparison
LODE vs MAIA Comparison
Compare LODE & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LODE
- MAIA
- Stock Information
- Founded
- LODE 2008
- MAIA 2018
- Country
- LODE United States
- MAIA United States
- Employees
- LODE N/A
- MAIA N/A
- Industry
- LODE Major Chemicals
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- LODE Industrials
- MAIA Health Care
- Exchange
- LODE Nasdaq
- MAIA Nasdaq
- Market Cap
- LODE 53.0M
- MAIA 46.7M
- IPO Year
- LODE N/A
- MAIA 2022
- Fundamental
- Price
- LODE $3.04
- MAIA $1.75
- Analyst Decision
- LODE Buy
- MAIA
- Analyst Count
- LODE 1
- MAIA 0
- Target Price
- LODE $26.00
- MAIA N/A
- AVG Volume (30 Days)
- LODE 489.5K
- MAIA 207.4K
- Earning Date
- LODE 05-08-2025
- MAIA 05-09-2025
- Dividend Yield
- LODE N/A
- MAIA N/A
- EPS Growth
- LODE N/A
- MAIA N/A
- EPS
- LODE N/A
- MAIA N/A
- Revenue
- LODE $3,376,027.00
- MAIA N/A
- Revenue This Year
- LODE $33.58
- MAIA N/A
- Revenue Next Year
- LODE N/A
- MAIA N/A
- P/E Ratio
- LODE N/A
- MAIA N/A
- Revenue Growth
- LODE 102.20
- MAIA N/A
- 52 Week Low
- LODE $1.26
- MAIA $1.40
- 52 Week High
- LODE $10.10
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- LODE 60.74
- MAIA 45.76
- Support Level
- LODE $2.86
- MAIA $1.71
- Resistance Level
- LODE $3.37
- MAIA $1.85
- Average True Range (ATR)
- LODE 0.21
- MAIA 0.12
- MACD
- LODE 0.03
- MAIA -0.01
- Stochastic Oscillator
- LODE 70.27
- MAIA 15.38
About LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.